Norepinephrine–dopamine disinhibitor

Norepinephrine and dopamine disinhibitors (NDDIs) are a class of drugs which act at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain.[1]

Chemical structure of agomelatine (Valdoxan), the prototypical NDDI.

Agomelatine, an antidepressant which disinhibits norepinephrine and dopamine release in the frontal cortex by antagonizing 5-HT2C receptors,[2] was the first drug to be described as an NDDI.[3] While many other drugs also antagonize 5-HT2C receptors to some degree or another, they tend to be very non-specific in their actions, and as a result, the term "NDDI" has generally, though not always (for instance, fluoxetine has been called an NDDI in addition to SSRI due to its (weak) blockade of 5-HT2C),[4] been reserved for describing newer, more selective agents in which disinhibition of norepinephrine and dopamine release is their primary mechanism of action.

Another drug that has been referred to as an NDDI in the medical literature is flibanserin,[5] which is approved as a treatment for hypoactive sexual desire disorder in premenopausal women.[6] Flibanserin disinhibits norepinephrine and dopamine release in the prefrontal cortex by activating 5-HT1A receptors in this area.[7]

Aside from agomelatine, fluoxetine, and flibanserin, as of present, no other drugs have been described as NDDIs in the medical literature, despite the fact that many other existing drugs possess effects consistent with those of the definition of an NDDI. In any case, more drugs labeled specifically as NDDIs may be seen in the future.

See also

References
  1. Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 23 April 2012.
  2. Millan MJ, Gobert A, Lejeune F, et al. (September 2003). "The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways". The Journal of Pharmacology and Experimental Therapeutics. 306 (3): 954–64. doi:10.1124/jpet.103.051797. PMID 12750432.
  3. Stahl SM (October 2007). "Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism". The International Journal of Neuropsychopharmacology. 10 (5): 575–8. doi:10.1017/S1461145707008000. PMID 17681087.
  4. Stephen M. Stahl (27 March 2008). Depression and Bipolar Disorder: Stahl's Essential Psychopharmacology. Cambridge University Press. p. 80. ISBN 978-0-521-88663-5. Retrieved 23 April 2012.
  5. Stephen M. Stahl; S. M. Stahl (17 March 2008). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. p. 658. ISBN 978-0-521-67376-1. Retrieved 23 April 2012.
  6. Thorp J, Simon J, Dattani D, et al. (March 2012). "Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study". The Journal of Sexual Medicine. 9 (3): 793–804. doi:10.1111/j.1743-6109.2011.02595.x. PMID 22239862.
  7. Stahl SM, Sommer B, Allers KA (January 2011). "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". The Journal of Sexual Medicine. 8 (1): 15–27. doi:10.1111/j.1743-6109.2010.02032.x. PMID 20840530.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.